Skip to main content

54 627 (Everolimus 7.5 mg)

Pill with imprint 54 627 is White, Capsule-shape and has been identified as Everolimus 7.5 mg. It is supplied by Hikma Pharmaceuticals PLC.

Everolimus is used in the treatment of neuroendocrine carcinoma; breast cancer; organ transplant, rejection prophylaxis; subependymal giant cell astrocytoma; pancreatic cancer and belongs to the drug classes mTOR inhibitors, selective immunosuppressants. There is positive evidence of human fetal risk during pregnancy. Everolimus 7.5 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for 54 627

Everolimus 7.5 mg 54 627

Everolimus

Imprint
54 627
Strength
7.5 mg
Color
White
Shape
Capsule-shape
Availability
Prescription only
Drug Class
Mtor inhibitors, Selective immunosuppressants
Pregnancy Category
D - Positive evidence of risk
CSA Schedule
Not a controlled drug
Labeler / Supplier
Hikma Pharmaceuticals PLC
Manufacturer
West-Ward Columbus Inc.
National Drug Code (NDC)
00054-0497

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.